Where Swiss research work meets US national interest.
Basel, less than an hour from Zurich by train, is the headquarters of Roche and Novartis, two of the largest pharmaceutical companies in the world by R&D investment, and their scientists routinely work on drug candidates and platform technologies with a direct connection to US public health priorities. ETH Zurich and its sister institution EPFL in Lausanne are both consistently ranked among the top technical universities in the world, and their faculty frequently conduct research — in AI, climate technology, quantum computing, and biomedicine — with clear relevance to US policy priorities.
NIW does not require an employer sponsor, a job offer, or PERM labor certification. Instead, the petitioner argues directly to USCIS, under the Matter of Dhanasar framework, that their proposed endeavor has substantial merit and national importance, that they are well positioned to advance it, and that waiving the labor certification requirement benefits the United States on balance. Swiss finance professionals are a harder fit for NIW than for EB-1A or O-1A, since the national-importance prong requires more than high compensation.
The three prongs Swiss applicants must satisfy.
USCIS evaluates every NIW petition under the framework established in Matter of Dhanasar (2016). All three prongs must be met.
Substantial merit & national importance
The proposed endeavor — a drug candidate, a research program, a technology platform — must have both substantial merit (intrinsic value) and national importance (broader significance to the US beyond the petitioner's own career).
Well positioned to advance it
Education, skills, publications, patents, prior success, and institutional resources — an ETH Zurich or EPFL faculty appointment, or a senior R&D role at Roche or Novartis, are strong evidence here.
Balance favors waiver
On balance, it benefits the US to waive the job offer and labor certification requirements — typically straightforward for researchers whose work does not fit a standard occupational category.
What qualifying records look like here.
Representative profiles from Swiss NIW petitions. Identifying details have been generalized.
Biomarker-driven treatment selection for solid tumors
Next-generation battery materials for grid-scale energy storage
Wearable biosensors for early detection of chronic disease
Why NIW and E-2 solve different problems.
Switzerland's E-2 treaty, one of the oldest such agreements with the US, is a capital-driven nonimmigrant category for founders and investors — it requires an active investment and ongoing direction of the enterprise, and it does not lead to a green card. NIW is a merit-driven immigrant category for individual researchers and scientists whose work carries national importance, requiring no investment and no employer sponsor.
For Swiss pharmaceutical scientists and ETH Zurich or EPFL researchers, NIW is frequently the most direct route to a green card, and it can be pursued while working in the US under an O-1A nonimmigrant visa using overlapping evidence.
Switzerland holds one of the oldest E-2 Treaty Investor agreements with the United States, dating to an 1850 treaty of friendship, commerce, and navigation. E-2 is a nonimmigrant, capital-driven category and does not lead to permanent residence. NIW is the more direct path to a green card for Swiss researchers whose work has national importance.